Brainomix

Brainomix is a University of Oxford spin-out specializing in the creation of AI-powered imaging biomarkers and software solutions that enable precision medicine and better clinical treatment decisions. Founded in 2010 by Michalis Papadakis and Andrew Charles Barker, the company's flagship product—Brainomix 360—is a comprehensive stroke AI imaging platform that provides real-time analysis tools including e-ASPECTS, e-CTA, e-CTP, and e-MRI to support neurologists, interventionalists, and radiologists. The platform is used in over 30 countries, processes a patient scan every 3 minutes, and is backed by 56+ clinical publications. Brainomix also has an e-Lung product for automated AI-powered solid tumor assessment. The company is backed by Boehringer Ingelheim Venture Fund, Parkwalk, and IP Group Hostplus Innovation Fund, and has received FDA clearance for its stroke AI imaging software.